A natural product for depression, fatigue or to slow the aging process, DHEA is a natural substance obtained from the barbasco root. It is synthesized in pharmaceutical labs and used to treat conditions such as depression and adrenal fatigue. Natural DHEA levels decline with age and some studies have shown that adequate levels of DHEA in the body can actually slow the aging process.
- Technical Specs
DHEA plus capsules may be a useful nutritional supplement for individuals who wish to support the body’s normal DHEA and pregnenolone functions.
Ingredients / Formula
Each capsule contains:
- DHEA (Dehydroepiandrosterone) 25 mg
- Progenelone (3-alpha-hydroxy-5-betapregnen-20-one) 25 mg
As a dietary supplement, take 1- 2 capsules daily, or as directed by the physician.
Please consult your physician before using this product. Not to be taken by individuals under the age of 18. Do not use this product if you have breast, uterine, ovarian or prostate problems. If you are at risk for or have prostate, breast, uterine or ovarian cancer you should not use this product. If you are pregnant, nursing or taking any prescription medication, especially other hormones or MAOIs (Monoamine Oxidase Inhibitors) consult with your physician before using this product. This product may cause changes in liver function, alterations in hormone profiles, increased facial hair, acne, and mood swings. This product may cause virilization in women.
Store in a cool, dry place, away from direct light. Keep out of reach of children.
- Extended Information
Araneo B, Dowell T, Woods ML, et al. DHEAs as an effective vaccine adjuvant in elderly humans. Proof-of principle studies. Ann N Y Acad Sci 1995; 774:232-248.
Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab 1996;81:59-64.
Barrett-Connor E, Kritz-Silverstein D, Edelstein SL. A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women. Am J Epidemiol 1993;137:201-206.
Berdanier CD, Parente JA, Jr., McIntosh MK. Is dehydroepiandrosterone an antiobesity agent? FASEB J 1993;7:414-419.
Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995;64:1027-1031.
Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993;150:5219-5230.
De Pergola G, Triggiani V, Giorgino F, et al. The free testosterone to dehydroepiandrosterone sulfate molar ratio as a marker of visceral fat accumulation in premenopausal obese women. Int J Obes Relat Metab Disord 1994;18:659-664.
De Pergola G, Cospite MR, Giagulli VA, et al. Insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone sulfate in obese women. Int J Obes Relat Metab Disord 1993;17:481-483.
De Pergola G, Giagulli VA, Garruti G, et al. Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. Metabolism 1991;40:187-190.
Doostzadeh J and Morfin R. Studies of the enzyme complex responsible for pregnenolone and dehydroepiandrosterone 7 Alpha-hydroxylation in mouse tissues. Steroids 1996; 61(10):613-620.
Fava M, Rosenbaum JF, MacLaughlin RA, et al. Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res 1989;28:345-350.
Flood J, Morley J, Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci USA 1992; 89:1567-1571.
Glaser JL, et al. Elevated serum dehydroepiandrosterone sulfate levels in practitioners of the Transcendental Meditation (TM) and TM-Sidhi programs. J Behav Med. 1992;15(4):327-341.
Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone sulfate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. Ann Rheum Dis 1993;52:211-214.
Herranz L, Megia A, Grande C, Gonzalez-Gancedo P, Pallardo F. Dehydroepiandrosterone sulfate, body fat distribution and insulin in obese men. Int J Obes Relat Metab Disord 1995;19:57-60.
Hidalgo A, et al. Calcium and depolarization-dependent effect of pregnenolone derivatives on uterine smooth muscle. Gen Pharmacol 1996; 27(5):879-885.
Hornsby PJ, et al. Changes in gene expression and DNA methylation in adrenocortical cells senescing in culture. Mutat Res 1991;256 (2-6):105-113.
Isaacson R, Varner J. The effects of pregnenolone sulfate and ethylestrenol on retention of a passive avoidance task. Brain Res 1995; 689:79-84.
Ishihara F, Komatsu M, Yamada T, et al. Role of dehydroepiandrosterone and dehydroepiandrosterone sulfate for the maintenance of axillary hair in women. Horm Metab Res 1993;25:34-36.
Jakubowicz DJ, Beer NA, Beer RM, Nestler JE. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J Clin Endocrinol Metab 1995;80:3373-3376.
Koenig H, et al. Progesterone synthesis and myelin formation by Schwann cells. Science 1995; 268(5216):1500-1503.
Koo E, Feher KG, Feher T, Fust G. Effect of dehydroepiandrosterone on hereditary angioedema. Klin Wochenschr 1983;61:715-717.
Leblhuber F, Neubauer C, Peichl M, et al. Age and sex differences of dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer's disease (AD).Psychopharmacology (Berl) 1993;111:23-26.
Legrain S, Berr C, Frenoy N, Gourlet V, Debuire B, Baulieu EE. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995;41:343-351.
Loviselli A, Pisanu P, Cossu E, et al. Low levels of dehydroepiandrosterone sulfate in adult males with insulin dependent diabetes mellitus. Minerva Endocrinol 1994;19:113-119.
Maione S, et al. Pregnenolone sulfate increases the convulsant potency of NMDA in mice. Eur J Pharmacol 1992; 219(3):477-479.
Majewska M, Mienville J, Vicini S. Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA neurons. Neuroscience Letters 1988;90:279-284.
Mathis C. et al. The neurosteroid pregnenolone sulfate blocks deficits induced by a competitive NMDA antagonist in active avoidance and lever-press learning tasks in mice. Neuropharmacology 1996; 35(8): 1057-1064.
Mendoza-Hernandez G, Libreros-Minotta CA, and Rendon JL. Detergent solubilization of 3Beta-hydroxysteroid dehydrogenase from dog pancreas. Comp Biochem Physiol B. 1996; 115B(2): 273-279.
Miklos S. Dehydroepiandrosterone sulfate in the diagnosis of osteoporosis. Acta Biomed Ateneo Parmense 1995;66:139-146.
Montanini V, Simoni M, Chiossi G, et al. Age-related changes in plasma dehydroepiandrosterone sulfate, cortisol, testosterone and free testosterone circadian rhythms in adult men. Horm Res 1988;29:1-6.
Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-1367.Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990;71:696-704.
Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 1992;6:3073-3075.
Nordin BE, Robertson A, Seamark RF, et al. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 1985;60:651-657.
Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992;75:1002-1004.
Roberts E. Pregnenolone-from Selye to Alzheimer and a model of the pregnenolone sulfate binding site on the GABA receptor. Biochemical Pharmacology 1995; 49:1-16.
Schumacher M, Robel P, and Baulieu EE. Development and regeneration of the nervous system: A role for neurosteroids. Dev Neurosci. 1996; 18(1-2):6-21.
Smith CP, Dunger DB, Williams AJ, et al. Relationship between insulin, insulin-like growth factor I, and dehydroepiandrosterone sulfate concentrations during childhood, puberty, and adult life. J Clin Endocrinol Metab 1989;68:932-937.
Szathmari M, Szucs J, Feher T, Hollo I. Dehydroepiandrosterone sulfate and bone mineral density. Osteoporos Int 1994;4:84-88.
Taelman P, Kaufman JM, Janssens X, Vermeulen A. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late postmenopause. Maturitas 1989;11:65-73.
Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 1990;14:457-463.
Van Vollenhoven RF, Engelman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994;37:1305-1310.
Wang M, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5-alpha-pregnane-3,20-dione and 3-alphahydroxy-5-alpha-prenan-20-one. J Clin Endocrinol Metab. 1996; 81(3):1076-1082.
Wolkowitz OM, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997;41(3):311-318.
Yen SS, Morales AJ, Khorram O. Replacement of DHEA in Aging Men and Women Potential Remedial Effects. Annals of the New York Academy of Sciences. 1995; 774:128-142.
Young J, et al. Neurosteroids in the mouse brain: Behavioral and pharmacological effects of a 3Betahydroxysteroid dehydrogenase inhibitor. Steroids 1996; 61(3):144-149.
For more information on DHEA Plus™ visit douglaslabs.com
† These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.
© 2012 Douglas Laboratories. All Rights Reserved
600 Boyce Road
Pittsburgh, PA 15205